In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Reapplix A/S

Reapplix ‘Focused Exclusively’ On US Wound Patch Launch After Securing Reimbursement

Reapplix’s CEO tells Medtech Insight the Danish group now has the funds to launch its biological wound healing patch in the US for treating patients with diabetic foot ulcers.

Wound Healing & Tissue Repair Diabetic Care

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.

Deals Financing

Reapplix Eyes US Market With Trial Results For Wound-Healing Tech

Following the presentation of results from a randomized trial, Reapplix is ramping up its commercial operations with the hire of a new US president to lead sales of its wound-healing platform, LeucoPatch.

Clinical Trials Research & Development

Reapplix Seals In More Funding For Diabetic Foot Ulcer Patch

Reapplix, an emerging autologous cell-based wound therapy specialist, has secured additional funding that will take the company through the next year before it gets “market-ready” to launch its diabetic foot ulcer treatment in the US and EU.

Diabetic Care Wound Management
See All

Company Information

  • Industry
  • Medical Devices
UsernamePublicRestriction

Register